Universal Registration Document Including The Annual Financial Report

Overview

The report highlights clinical proof of principle for Transgene's individualized TG4050 cancer vaccine, with the Phase II part of the trial launched in 2024. It also describes formal ESG oversight by the Board and ESG Committee, including review of a dual materiality matrix. Environmental reporting includes a 2,381 metric tons of CO2e footprint for fiscal year 2023 and a 50% renewable share of company electricity.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 10 April 2025
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services